Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Apr 21, 2017 4:24pm

178 Views

Post# 26150920

RE:Exempt Distribution

Toniv,

I looked at the document that plapper informed us about on SEDAR. I disagree with yours and Koo-Koo2's interpretation that these shares were purchased by the Resverlogix CFO Brad Cann. The way I read the document, Brad Cann was the individual certifying the report (item 10). In the text for item 10, it reads "If the individual completing and filing the report is different from the individual certifying the report, provide their name and contact details in Item 11." The person listed in item 11 is Lloyd McLellan, with a title of "Solicitor" of the company "BORDEN LADNER GERVAIS LLP". Am I reading this correctly that Lloyd McLelan/Borden Ladner Gervais LLP was the purchaser?

BearDownAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market